We've helped cure
more than a
million patients.

Watch what's next.

Great Chemistry Cures

At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured more than one million people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patients’ lives, and this drives us to do it again in other disease areas.

Pipeline »

Great Chemistry Cures

At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured more than one million people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patients’ lives, and this drives us to do it again in other disease areas.

Pipeline »

great-chemistry-shapes-lg-blue

Virology

great-chemistry-shapes-lg-ltblue

Immunology

About Us

Enanta’s heritage is steeped in scientific expertise and a track record of effective innovation. Without either, we wouldn’t be where we are today. We are dedicated to applying these capabilities and experience each day in hopes of improving patients’ lives. We’ve done it before, and we’re determined to do it again.

About »

February 10, 2026

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Read More »

February 9, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Read More »

January 8, 2026

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

Read More »